États-Unis · Bourse & Finance · MarketWatch

Bristol Myers Squibb Says FDA Approves Heart Disease Treatment Camzyos for Pediatric Patients

Publié par MarketWatch · États-Unis il y a 12 h

Bristol Myers Squibb said the Food and Drug Administration approved Camzyos to treat symptomatic obstructive hypertrophic cardiomyopathy in adults and pediatric patients weighing…

Lire l'article complet sur MarketWatch Connectez-vous pour sauvegarder

MediaNews présente le titre et le résumé publiés par le média. L'article complet se lit sur le site de l'éditeur. (www.marketwatch.com)

Bristol Myers Squibb Says FDA Approves Heart Disease Treatment Camzyos for Pediatric Patients

À lire aussi

MetaMask exits Lido validators as it investigates security incident

Read the letter Trump is sending along with $500 checks to nearly 1 million Americans for ACA 'refunds'

Iran’s Disappearing Oil Is Becoming Everyone’s Problem

California Gov. Gavin Newsom bans AI 'robo bosses' in landmark state law, reversing his earlier veto

Google releases Gemini 4 Argon, called its most powerful model yet

Transocean gets DOJ approval for Valaris acquisition

Bristol Myers Squibb Says FDA Approves Heart Disease Treatment Camzyos for Pediatric Patients

Partager

À lire aussi

MetaMask exits Lido validators as it investigates security incident

Read the letter Trump is sending along with $500 checks to nearly 1 million Americans for ACA 'refunds'

Iran’s Disappearing Oil Is Becoming Everyone’s Problem

California Gov. Gavin Newsom bans AI 'robo bosses' in landmark state law, reversing his earlier veto

Google releases Gemini 4 Argon, called its most powerful model yet

Transocean gets DOJ approval for Valaris acquisition